Verastem
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 1 week.
- Its last 5 Sell calls were followed by roughly flat moves (-0%) three months out.
- Recent price momentum is -21.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 16.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 82.9% | Better than 92% |
| Operating margin | -550.3% | Better than 4% |
| Net margin | -677.6% | Better than 3% |
| Return on equity | -1,480.2% | Better than 0% |
| Return on invested capital | -269.3% | Better than 0% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -8.1% | Better than 55% |
| 6-month return | 49.3% | Better than 95% |
| 12-month return (ex latest month) | 0.6% | Better than 34% |
| Distance below 52-week high | 41.5% | Better than 27% |
Financial Health C-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.1x | Better than 74% |
| Debt to assets | 35.4% | Better than 33% |
| Interest coverage | -183.1x | Better than 4% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 192.3% | Better than 94% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 6.86
- Open
- 6.63
- Day range
- 6.25 - 6.82
- Avg price
- 6.47
- Volume
- 3.25M
- Turnover
- 21.02M
- Turnover ratei
- 2.74%
- Volume ratioi
- 1.11
- Amplitudei
- 8.24%
- 52-week rangei
- 3.43 - 10.82
Valuation
- P/Ei
- -2.10
- P/E (TTM)i
- -3.44
- P/Bi
- 79.13
- EPSi
- -3.02
- Book value / shi
- 0.08
- Net profit
- -380.56M
- Net assets
- 10.08M
Share structure
- Market cap
- 797.67M
- Float capi
- 750.95M
- Shares out
- 126.01M
- Float sharesi
- 118.63M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
41.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-9.60M net over the window
Short interest
- Shares short
- 19.67M
- % of floati
- 16.20%
- Days to coveri
- 5.17
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Verastem (VSTM)?
Verastem last traded at 6.33. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Verastem's market cap?
About 797.67M.
What is the P/E ratio of Verastem?
The trailing twelve-month P/E is -3.44, below its own 5-year average of 10.89 — toward the bottom of its historical range (0.56% percentile). See the Valuation tab for the full history.
Does Verastem pay a dividend?
Verastem does not currently pay a regular dividend.
Is Verastem a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 18.50, which implies 192.3% upside from the current price. This is not investment advice.
What is Verastem's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Verastem a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Verastem discussion 0 comments